NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) news coverage focuses on its progress as a clinical-stage life sciences and biopharmaceutical company developing central nervous system therapeutics designed to overcome the blood-brain barrier. News releases frequently highlight updates from Phase 1/2a and Phase 2a clinical trials of intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma and other high-grade gliomas, as well as regulatory and operational milestones across its CNS oncology pipeline.
Investors following NTHI news can expect detailed reports on radiographic response rates, progression-free survival and long-term survival outcomes from NEO100 studies, along with safety and tolerability findings associated with prolonged intranasal dosing. Additional news items describe the advancement of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors, including U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb clinical development.
Company announcements also cover strategic partnerships and corporate developments, such as the establishment of the NuroMENA subsidiary in the United Arab Emirates, a Master Services Agreement with IROS (an M42-affiliated contract research organization), and share exchange or acquisition transactions disclosed in Form 8‑K filings. Updates on non-dilutive NIH STTR funding, intellectual property expansion, and NeOnc’s AI and 3D bioprinting initiatives for sonodynamic therapy research with NEO100 are also common themes.
By monitoring this NTHI news feed, readers can track NeOnc’s clinical data readouts, regulatory interactions, regional expansion efforts and financing-related disclosures as they are released through press announcements and SEC-referenced communications.
NeOnc Technologies Holdings (NTHI) is scheduled to meet the FDA on November 17, 2026, about NEO212’s next clinical-development steps.
The End-of-Phase 1 meeting will cover a proposed Phase 2 patient population, trial design, endpoints and dose, and potential paths toward a marketing application. NEO212 completed Phase 1 dose escalation with a recommended Phase 2 dose of 610 mg. Reported tumor reduction of approximately 60% in one glioblastoma patient and approximately 16 months of stable disease in another patient with brain metastasis remain individual observations, not controlled evidence of efficacy. NEO212 also received UAE IND authorization.
For NEO100, Phase 2a six-month progression-free survival was 48.9% versus a prespecified 20% benchmark (p=0.0047). NeOnc completed a $15 million offering at $4.20 per share with warrants, then redeemed 6,000 Series A preferred shares for $6 million in cash.
NeOnc Technologies Holdings (NTHI) is scheduled to discuss NEO212 trial design and dosing with the FDA on November 17, 2026. The End-of-Phase 1 meeting will cover the proposed patient population, endpoints and a possible accelerated-approval pathway. Phase 1 reached a maximum tolerated dose of 810 mg, and the recommended Phase 2 dose is 610 mg. One patient had approximately 60% tumor reduction and 21 months of disease control; individual observations do not establish efficacy.
For NEO100, NeOnc reported six-month progression-free survival of 48.9% against a prespecified 20% benchmark and median overall survival of 26.09 months. Roth Capital initiated coverage with a $20 price target. NeOnc also raised institutional capital in a September offering priced at $4.20 per share with accompanying warrants.
NeOnc Technologies (NTHI) will meet FDA on November 17, 2026, to discuss the next stage of NEO212 development.
The End-of-Phase 1 meeting follows completion of dose escalation in the NEO212-01 Phase 1/2 trial. FDA authorized NeOnc to proceed with the trial’s Phase 2a and 2b portions in September 2025. NeOnc plans to seek feedback on the proposed patient population, trial design, endpoints, dose and evidence needed for a future marketing application. It also intends to discuss whether a proposed design could support accelerated approval; the scheduled meeting does not establish FDA agreement.
Dose escalation stopped after a dose-limiting toxicity at 810 mg; 610 mg was selected as the recommended Phase 2 dose. One patient with recurrent glioblastoma had a partial response, including an approximately 60% reduction in tumor size, followed by disease control lasting 21 treatment months. A patient with lung cancer metastatic to the brain had stable disease for approximately 16 months. These individual outcomes do not establish efficacy and require confirmation in larger studies.
NeOnc Technologies Holdings (NTHI) received new coverage from Roth Capital analyst Jonathan Aschoff in a report published September 24, 2026.
In August, NeOnc reported topline Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma. Six-month progression-free survival was 48.9% against a prespecified 20% benchmark; median overall survival was 26.09 months. NeOnc plans to request an FDA Type B meeting to discuss a path toward registration. Roth expects an End-of-Phase 2 meeting in October and sees potential pivotal-trial starts before the end of 2026. Those dates are analyst expectations, not confirmed timelines.
NeOnc raised $15 million through a September registered direct offering priced at $4.20 per share, with accompanying warrants exercisable at $4.20. NEO212 Phase 1 work established a recommended Phase 2 dose of 610 mg after dose escalation reached its protocol-defined maximum tolerated dose.
NeOnc Technologies Holdings (NTHI) reported Phase 2a data for its intranasal brain cancer therapy NEO100 in recurrent or progressive Grade III/IV IDH1-mutant glioma. The study showed six-month progression-free survival of 48.9% versus a prespecified 20% benchmark, with a reported p-value of 0.0047. Median overall survival was 26.09 months, and 5 of 24 patients remained on treatment at data cutoff, with no major toxicities and mostly low-grade adverse events.
The company aims to pursue a targeted development path in this biomarker-defined population and plans to seek a Type B FDA meeting to discuss a potential registrational pathway. The NEO100 data suggest a clinical signal that may warrant a larger, better-controlled trial and could support broader interest in intranasal “nose-to-brain” delivery approaches.
NeOnc Technologies Holdings (NTHI) reported August 12, 2026 topline Phase 2a data for NEO100, an intranasal formulation of purified perillyl alcohol, in 24 patients with recurrent or progressive Grade III/IV IDH1‑mutant glioma.
The open‑label study’s primary endpoint, six‑month progression‑free survival, was 48.9% versus a prespecified 20% historical benchmark, with a one‑sided p‑value of 0.0047 and a 26.3–68.1% confidence interval. Median overall survival was 26.09 months, and overall survival at six months was 86.7%. The company reported no major toxicities, with predominantly low‑grade adverse events, under a home‑use intranasal dosing regimen four times daily in 28‑day cycles.
Five of 24 patients remained on treatment at data cut; individual patients showed prolonged benefit, and NeOnc plans to seek a Type B FDA meeting to discuss a potential registrational path.
NeOnc Technologies (NTHI) redeemed all 6,000 outstanding shares of its Series A Convertible Preferred Stock for $6 million in cash, issuing no new common shares and removing a potential source of discounted-share conversion.
The redemption follows a recently announced $15 million registered direct offering, which the company said was structured to fund this buyback and simplify the capital structure. The Series A, issued in June for $5 million, carried a four-month cash-redemption window and could have converted into common stock at 80% of the lowest closing price over the prior five trading days, subject to a $1 floor, had it not been redeemed.
Alongside this capital move, NeOnc highlighted clinical progress: NEO100 reported topline Phase 2a data in recurrent IDH1-mutant high-grade glioma with six-month progression-free survival of 48.9% versus a 20% benchmark and median overall survival of 26.09 months, while NEO212 completed Phase 1 dose escalation, set a recommended Phase 2 dose of 610 mg, and received UAE IND authorization.
NeOnc Technologies (NTHI) redeemed for cash all 6,000 outstanding shares of its Series A Convertible Preferred Stock at an aggregate stated value of $6.0 million. No Series A Preferred shares remain outstanding, and no common stock was issued in the redemption.
The company used a portion of net proceeds from its recently completed $15 million registered direct offering to fund the buyback, which was completed within the contractual four‑month redemption window. By acting before the preferred stock’s discounted conversion feature became available, NeOnc avoided potential common share dilution and simplified its capital structure while continuing to advance its Phase II CNS cancer candidates NEO100 and NEO212.
NeOnc Technologies Holdings (NTHI) reported substantial insider buying following positive Phase 2a data for its brain cancer candidate NEO100.
Since announcing Phase 2a results on August 12, two senior executives have bought approximately $629,000 of stock in open‑market transactions using personal funds, totaling 160,016 shares combined. CEO Amir F. Heshmatpour’s post‑results purchases reached 111,000 shares for about $418,700, including 35,000 shares on September 15 for roughly $115,400 at a weighted average price near $3.30. Founder and CMO/CSO Thomas C. Chen acquired 49,016 shares for about $210,000.
The NEO100‑01 Phase 2a study met its primary endpoint with six‑month progression‑free survival of 48.9% versus a 20% benchmark, a reported p‑value of 0.0047, and median overall survival of 26.09 months. NeOnc also completed Phase 1 dose escalation for its second program, NEO212, and recently closed a $15 million registered direct offering to support ongoing clinical work.
NeOnc Technologies Holdings (NTHI)/b) reported that senior executives have purchased approximately $629,000 of company stock in open-market transactions since August 12, 2026, following positive NEO100 Phase 2a results.CEO Amir F. Heshmatpour bought an additional 35,000 shares on September 15, 2026 for about $115,400 at a weighted average price of $3.30 per share, bringing his total post-results purchases to 111,000 shares for roughly $418,700 at an average cost of $3.77 per share. Founder and Chief Medical Officer Thomas C. Chen acquired 49,016 shares for about $210,000, bringing combined executive purchases to 160,016 shares. The NEO100-01 Phase 2a trial met its primary endpoint, with six-month progression-free survival of 48.9% versus a 20% benchmark (p=0.0047) and median overall survival of 26.09 months. NeOnc also highlighted completion of Phase 1 dose escalation and a recommended Phase 2 dose for NEO212, and referenced a previously announced $15 million registered direct offering.